Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 111-120 of 416 for multiple

Edit search filters
  1. Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma

    Jacksonville, FL, Rochester, MN, Scottsdale/Phoenix, AZ

  2. A Study Comparing Anitocabtagene Autoleucel To Standard Of Care Therapy In Participants With Relapsed/ Refractory Multiple Myeloma (IMMagine-3)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  3. A Study To Evaluate The Safety, Effectiveness And Tolerable Dose Of BMS-986393 In Novel Combinations In Participants With Relapsed And/or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

    Jacksonville, FL

  5. A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  6. Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ

  7. S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  8. Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial

    Rochester, MN

  9. A Study Evaluating the Addition of Venetoclax (ABT-199) to Patients with Multiple Myeloma who are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Rochester, MN

  10. Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma

    Rochester, MN

.

Mayo Clinic Footer